Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
ABSTRACT The lowest dosage of empagliflozin (10 mg) showed similar benefits on glycated hemoglobin (HbA1c) level, body weight, blood pressure, and total and cardiovascular mortality in comparison with the highest...
Conclusion/Relevance: In the indirect meta-analysis, canagliflozin 300 mg ranked the highest regarding reductions in HbA1c and body weight. The remaining medications and dosages were clinically similar, despite some statistically significant differences among them. Canagliflozin 300 mg seems to be more potent in reducing HbA1c and body weight...
Share
Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35234250/
Diabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be...
Conclusion/Relevance:We show that EMPA reduces vascular leakage indicated by lower albumin staining in the vitreous humor and diminishes expression of the pathogenic factor VEGF in the retina. Additionally, EMPA significantly alters the retinal genetic signature. Our findings suggest that SGLT2 inhibition may be a useful therapeutic approach to...
Share
Patterns of Care for First-detected Atrial Fibrillation: Insights from the Get With The Guidelines Atrial Fibrillation Registry
Source : https://www.heartrhythmjournal.com/article/S1547-5271(22)00210-7/fulltext
Despite multiple trials comparing rate with rhythm control, there is no consensus on optimal management of first-detected atrial fibrillation (AF). We analyzed current patterns of care for first-detected AF in...
Conclusions: Less than half of the patients with first-detected AF receive rhythm control at admission. Given recent trial results, further studies should assess the long-term impact of rhythm control on patients’ symptoms and quality of life, cardiovascular morbidity, and mortality
Share
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35219331/
Randomized Controlled Trial doi: 10.1186/s12933-022-01463-2. 1 Department of Cardiology, Research Unit of Cardiology, Odense University Hospital, Odense, Denmark. [email protected]. 2 Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark. [email protected]....
Conclusion: Empagliflozin increased plasma levels of GDF-15 in patients with HFrEF, with no concomitant increase in hsTNT nor hsCRP.
Share
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35228754/
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when...
Conclusion: "The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial".
"
Share